Directory · CN
Biotechnology Research in China
A register of firms and the professionals working at them in the Biotechnology Research sector based in China. Browse the public index, then filter or export on Kipplo.
Companies
1.3K on file
Bgi Group
The Human Genome Project (HGP) is considered as one of the greatest scientific achievements of the last century. BGI was founded in in order to participate in this significant research project. Since then, BGI has integrated innovative research, technology and business development with both non-profit and profit operations.
10001+ staff
China National Biotec Group Company Limited
China National Biotec Group (CNBG), is a subsidiary of China National Pharmaceutical Group corporation (SINOPHARM), and has 6 subordinate biological products research institutes in Beijing, Changchun, Chengdu, Lanzhou, Shanghai and Wuhan as well as Beijing Tiantan Biological Products Co, Ltd. CNBG is a professional institute which has the longest history in vaccine and blood production research and development in China, and is the biggest biotech corporation combines research, development, production and supply in one. To date, the total assets of the group is 15.6 billion RMB, main operating revenue exceeds 5 billion RMB, is the fourth biggest vaccine manufacturer in the world. The development of CNBG represents the development history of Chinese biological products industry. CNBG developed and produced the earliest vaccine of smallpox, cholera, typhoid and rabies as well as diphtheria antitoxin etc, separated the first Penicillium strain in China. Since the establishment of P.R.C, CNBG and it's subordinate biological products research institutes take the responsibility of production of biological products for preventing, controlling and eradiating of infectious diseases, made great contribution in China's endeavor of eradiating smallpox, eliminating polio, reducing the incidence of various infectious diseases including measles, diphtheria, pertussis, epidemic encephalitis B, DCSM and hepatitis B. CNBG has strong industrialization capacity, possesses production bases in six main cities with nearly one hundred production line up to GMP standard, with the ability of manufacture more than 200 biomedicine products for prevention, treatment and diagnoses, among which there are 24 national first and second-class new medicine, 34 types of vaccines preventing 24 viruses and bacteria whereas there are 41 types of vaccines preventing 26 viruses and bacteria can be produced in China. CNBG is the biological products corporation with the most types and the largest output of vaccines and blood products in China. CNBG does its best to serve the national immunity programme, takes more than 80% production assignment of vaccines for national immunity programme. Meanwhile, with its technology advantage, contribute to research, production, facility and technology upgrade for serious infectious diseases prevention and control products, made great contribution in fighting against "SARS", disaster relief and resisting globally spread H1N1. CNBG has tremendous scientific research strength, owning a biotec experts team including academician of Chinese Academy of Engineering, more than 70 new medicine examination and approval experts of National Food and Drug Administration, more than 10 comment experts of National Science Foundation Committee, and more than 170 experts with national government allowances. CNBG is one of the first group of corporations with doctor and master degree-conferring qualification, owns 1 doctor site, 5 master sites and 5 post-doc sites. During 1989 to now, accumulatively over 700 master and 50 PHD students were trained here. CNBG has great achievement in scientific research, assumes responsibility of a lot of key projects of China 863 plan and "twelfth five" science support plan. There are more than 10 projects filled the blank in China and many production possessed intellectual property, 26 of them obtained the first and second prize of national science progress prize, more than 180 obtained provincial prize. In 2008, CNBG was named the first group of "innovative corporation" by National Scienceand Technology department, State Finance Authorities and Chinese National Federation of Trade Unions.
10001+ staff
Beigene
Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible. To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.
1 to 10 staff
Biogenex
BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of cancer of unknown primary (CUP) and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully automated molecular pathology work stations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life science research and diagnostics. With a team of accomplished technical, business and customer support professionals, BioGenex strives to reach the pinnacle of the global molecular medicine industry by offering cost-effective solutions for life sciences research and personalized medicine. Additionally, the partnership of BioGenex with top-notch universities, hospitals, and the pharmaceutical and biotechnology industry drives its innovative research and product development activities. The company is also known for its pre- and post-sales customer support that complements the high quality products and solutions offered by the firm.
51 to 200 staff
Cell Signaling Technology Cst
Founded by research scientists in Cell Signaling Technology (CST) is a private, family-owned company that prides itself on operating as a research institute developing quality products for other researchers. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies. That's why all of our antibodies are painstakingly validated for multiple applications by our Ph.D. level scientists. And the same CST scientists who helped produce your antibody will also provide technical support, methods, and guidance needed to achieve the most reliable results. Check out our website! For Research Use Only. Not for Use in Diagnostic Procedures.
501 to 1000 staff
Repligen Corporation
FRAUD ALERT: Please take note that it has come to our attention that individuals purporting to work for Repligen are reaching out to prospective job applicants using fraudulent email addresses. All legitimate communications from Repligen will be sent from an individual with an email address ending in @repligen.com. If you have any concerns that a communication may be fraudulent and you would like to confirm whether it is, you may email legal@repligen.com and someone will respond. Repligen is a bioprocessing-focused life sciences company bringing over 40 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies. Repligen headquarters is in Waltham, Massachusetts and our manufacturing facilities are located around the world. We market our products globally through a direct commercial organization in the U.S, Europe and Asia, as well as through strategic partners in select markets.
1001 to 5000 staff
Eurofins China
Eurofins provides high standard quality assurance and control services, such as testing, certification, inspection, audits, technical and regulatory services, worldwide, to •Manufacturers, •Brand owners, •Distributors and trading companies •Buying associations, consumer associations, •And retailers
10001+ staff
Nelson Labs
Nelson Labs is a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. Nelson Labs serves over 3,500 customers across 15 facilities in the United States, Mexico, Asia, and Europe. We have a comprehensive array of over 800 laboratory tests supporting our customers from initial product development and sterilization validation, through regulatory approval and ongoing product testing for sterility, safety and quality assurance. We are regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. Learn more about Nelson Labs at Safeguarding Global Health® - with every test we complete.
501 to 1000 staff
Novogene
Novogene specializes in the application of advanced molecular biotechnology and high-performance computing in the research fields of life science and human health. Established in March 2011, Novogene strives to become a global leader in providing genetic science services and technology products. Novogene has set up operations and laboratories in the United States, the United Kingdom, Netherlands, Germany, as well as in China, Singapore and Japan. Novogene currently consists of a comprehensive, and interdisciplinary team, the majority of which hold advanced degrees from top universities in China and abroad. The company has established high-ux, large-scale gene sequencing and high-performance computing platforms, which support effectively the demands of life science research and medical health for big data analysis and storage. Novogene has served over 7,300 global customers, covering 90 countries and regions across 6 continents. We have cooperated extensively with many academic institutions and completed several advanced-level, international genomics research projects. By 2023, Novogene has co-published and/or been acknowledged in more than 22,850 articles in Science Citation Index, with an accumulative impact factor of more than 148,250. Our partners are worldwide and include more than 4,200 scientc research institutions and universities, more than 680 hospitals and over 2,400 pharmaceutical and agricultural enterprises. Currently, Novogene has obtained 356 software copyrights and 66 patents. As the leader in genome sequencing, Novogene’s business spans across scientific research for life science, medical research and technology services, storage-building sequencing platform services, gene sequencing, mass spectrometry and bio-information technology support for global research, scientific research institutions, hospitals, pharmaceutical R&D enterprises and agricultural enterprises.
1001 to 5000 staff
Sinovac Biotech Ltd
Sinovac Biotech Ltd.(SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
1001 to 5000 staff
Tse Systems
We help scientists see what really happens in a living animal - without stress, noise, or guesswork. TSE Systems builds tools for metabolic, behavioral, and physiological studies in rodents. Our setups keep animals in their home cage, reduce handling, and let you follow real biology over time - clean, steady, and easy to trust. Researchers come to us when they want data that holds up, automation that removes bias, and engineering that simply works. 140+ years of German design. Thousands of publications. One goal - help you run better studies with fewer animals and clearer answers. Follow us for insights, case examples, and new ways to strengthen in-vivo research. Learn more: Data Privacy Statement & Imprint:
51 to 200 staff
Angel Yeast
Founded in 1986, Angel Yeast Co, Ltd. is a global biotech leader specializing in yeast and fermentation. With 33 production bases and a presence in 170+ countries, we provide natural ingredient solutions for the baking, food taste, nutrition & health, and biotechnology industries. Supported by 12 applied science centers and 760+ R&D professionals, we collaborate with global partners to drive innovation that enhances health, efficiency, and sustainability. With over employees worldwide, we’re committed to advancing yeast technology and creating a better life through the power of biotechnology.
5001 to 10000 staff
Cobetter Filtration Group
As a global well-known company specializing in the R&D of membrane materials, we are committed to providing innovative filtration and purification solutions for the life science industry. With a wealth of technical expertise and senior engineer team, we offer a broad portfolio in filtration & purification and fluid management to researchers and biopharma, helping accelerate process development to commercial manufacturing. Our comprehensive products include laboratory consumables and instruments, TFF cassettes, hollow fibers, membrane chromatography, virus filtration, sterile filtration, and single-use solutions.
5001 to 10000 staff
Epredia
Every second of every hour of every day, 44 of our products are employed in the battle against cancer. Customers put their trust in Epredia over a billion times every year. Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific. Powered by trusted brands such as Shandon, Microm, Menzel Gläser and Richard-Allan Scientific, Epredia has a wide breadth of solutions that have and will continue to transform the anatomical pathology market. Today, we’re a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies. Since our humble beginnings in 1937, every product developed has been impacted by generations of employees who are committed to improving lives by enabling pathologists through enhancing precision cancer diagnostics. Find out how you can improve lives while advancing your career at #Epredia by visiting epredia.com/careers.#WhatWeDoMatters
1001 to 5000 staff
Everest Clinical Research
Everest Clinical Research ("Everest") is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. We serve some of the best-known companies and work with many of the most advanced drugs, biologics, and medical devices in development today. Everest has been an independent CRO since 2004 with a strong foundation as a statistical and data management center of excellence. Building on this foundation, Everest has successfully developed and established itself as a full-service CRO. Operating primarily in North America, with headquarters located in Markham, Ontario (Greater Toronto Area), Canada, with additional offices in Bridgewater, New Jersey, USA, Shanghai, China, Taipei, Taiwan, and Sofia, Bulgaria, Everest is known in the industry for its high quality deliverables, superior customer service, and flexibility in meeting clients’ needs. A dynamic organization with an entrepreneurial origin, Everest continues to experience exceptional growth and great success Quality is our backbone, customer-focus is our tradition, flexibility is our strength.that’s us…that’s Everest! Important Information for job candidates: Please be aware of cyber-security due to some fraudulent job scams. Everest will follow our standard and thorough recruitment process which will include video panel interviews: Everest email communication will come from an ecrscorp.com email address. Emails from other domains may not be from Everest. Everest will never ask for credit card information or charge fees at any time during the recruitment process. If something is portrayed as Everest but does not appear to be from Everest, please feel free to contact us at
501 to 1000 staff
Sansure Biotech Inc
Sansure Biotech Inc, a listed company in China, is a comprehensive provider of integrated diagnosis and treatment solutions, with independent and innovative gene technology at its core. Founded in 2008, with Changsha and Shanghai as its strategic hubs, Sansure has further expanded its global presence and established more than 40 subsidiaries and branches across China and key global markets including the UK, France, the US, Indonesia, the Philippines, Thailand, and beyond. With over 40% of employees dedicated to R&D, the company has pioneered a series of leading core technologies and developed over products, along with more than 2,200 kinds of high-quality testing services, covering reagent, instrument, quality control, technical training and service, independent clinical laboratory service, genetic testing service, biopharmaceutical, etc. These products and solutions are used by over benchmark hospitals and laboratories worldwide, serving billions of people across over 160 countries and regions. With unwavering determination, Sansure will continue to advance its transformation into a world-class life sciences enterprise. For more information, please contact us at info@sansure.com.cn
1001 to 5000 staff
Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
51 to 200 staff
Accutar Biotech
Overview: AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY. Products & Services: Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.
11 to 50 staff
Adagene
Adagene Inc.(Nasdaq: ADAG) is a biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform, composed of NEObody, SAFEbody™, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
201 to 500 staff
Bio-Thera Solutions
Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.
201 to 500 staff
Sinocare Inc
As a high-tech company, Sinocare Inc. has been dedicating itself to bio-sensor technology research & development, manufacturing and marketing of POCT products since its establishment in Aug,2002. Sinocare focuses intensively and extensively on the R&D of products and innovation of technology, casting our look into the future, to deliver significant benefits for people pursuing healthy living. In March, 2012, Sinocare Inc. was listed on Shenzhen Stock Exchange, abbreviated as "Sinocare" with stock code 300298. We passed ISO13485 and our products were certified by EU CE. The company's Sinocare glucometer series and its test strips has won an universal recognition from a large number of consumers thanks to its accuracy, simplicity and affordability. The product is not only popular in China, but also exports in large scale. Observing the values of “equality, honesty, innovation and excellence”, Sinocare conducts continuous innovation and establishes "portable laboratory" based on POCT product. The company aims at providing quality product and service for China’s chronic disease management, help chronic disease patients improve living quality and reduce the burden of social medical care system.
1001 to 5000 staff
Apollomics
Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West. Since our founding in 2015, under the leadership of our experienced management team with in-depth knowledge and expertise of the evolving cancer treatment landscape, we have built a pipeline of ten (10) drug candidates across 12 programs that focus on oncology, of which five (5) drug candidates are at clinical stage. The drug candidates in our existing pipeline can be categorized into three (3) groups based on their mechanisms of action, each of which contains drug candidates at different stages of development. The first group is “tumor inhibitors”, which consists of four (4) small molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells, one of which is our Core Product, a c-Met inhibitor. The second group is “anti-cancer enhancers”, which could enhance the anti-cancer effects of other treatments. This group comprises two (2) antagonists against a cell adhesion receptor, which are being developed as adjuncts to chemotherapy. The last group is “immuno-oncology drugs”, which take the advantage of the body’s immune system to fight cancer. This group comprises four (4) drug candidates, including mono-specific and bi-specific antibodies that releases the natural brakes of immune response against cancer cells, as well as a novel cancer vaccine. Having three (3) groups of drug candidates with different mechanisms of action would enable us to develop potential synergistic combination therapies that address unmet needs in cancer treatment. To learn more about Apollomics, visit our website at
51 to 200 staff
Biostorage Technologies, Inc
BioStorage Technologies, Inc. is the premier, global provider of comprehensive sample management solutions for the bioscience industry. Offering flexible onsite, offsite and hybrid models for the smartsourcing of research assets, BioStorage Technologies provides a complete life-cycle of sample management solutions. With an expert team of global sample consultants, industry-leading temperature-controlled storage facilities, and state-of-the-art virtual sample management and bioprocessing solutions, the company supports its customers in maximizing opportunities, minimizing risk and reducing costs. BioStorage Technologies, Inc. is a privately held, global corporation. For more information, visit or call +1 866 697 2675 for North America,+49 6155 898 1011 for Europe,+65 31576199 for Singapore and +86 10 8587 2390 for China.
51 to 200 staff
Casi Pharmaceuticals, Inc
CASI Pharmaceuticals, Inc.(NASDAQ: CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced FDA clearance of an IND application for CID-103, an anti-CD38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection (AMR). The Phase 1 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of CID-103 in patients with AMR.
51 to 200 staff
